JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

  NCT03978143

  Condition:   Healthy Volunteers
  Interventions:   Drug: Treatment A;   Drug: Treatment B;   Drug: Treatment C;   Drug: Treatment D;   Drug: Treatment E;   Drug: Treatment F;   Drug: Treatment G;   Drug: Treatment H
  Sponsor:   Pfizer
  Recruiting
• The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders

  NCT03953612

  Condition:   Cocaine-Related Disorders
  Interventions:   Drug: PREG 300/500 mg;   Drug: Placebos
  Sponsor:   Yale University
  Recruiting
• Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

  NCT03946111

  Conditions:   Binge-Eating Disorder;   Obesity
  Interventions:   Drug: Naltrexone and Bupropion;   Other: Placebo
  Sponsor:   Yale University
  Recruiting
• A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

  NCT03937258

  Condition:   Healthy
  Interventions:   Drug: PF-04965842;   Drug: Probenecid
  Sponsor:   Pfizer
  Recruiting
• Brief ROC Training Effects on Alcohol Drinking

  NCT03928626

  Conditions:   Binge Drinking;   Heavy Drinking;   Young Adult;   Heavy Drinker;   Alcohol Drinking;   Alcohol Drinking in College;   Drinking Behavior;   Drunkenness;   Drinking Excessive;   Drinking Problem;   Drink Too Much;   College Drinking
  Interventions:   Behavioral: Regulation of craving;   Behavioral: Control (NO REGULATION)
  Sponsor:   Yale University
  Recruiting
• Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

  NCT03926052

  Conditions:   Binge-Eating Disorder;   Obesity
  Interventions:   Drug: Lisdexamfetamine Dimesylate;   Drug: Placebo
  Sponsor:   Yale University
  Recruiting
• Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment

  NCT03924193

  Conditions:   Binge-Eating Disorder;   Obesity
  Interventions:   Drug: Lisdexamfetamine Dimesylate;   Behavioral: Cognitive-Behavioral Therapy;   Other: Combination LDX and Cognitive-Behavioral Therapy
  Sponsor:   Yale University
  Recruiting
• Transcranial Direct Current Stimulation and Fear Extinction

  NCT03907917

  Condition:   Anxiety Disorders
  Intervention:   Device: tDCS
  Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
  Recruiting
• The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders

  NCT03872128

  Condition:   Alcohol Use Disorder
  Interventions:   Drug: Pregnenolone;   Other: placebo
  Sponsor:   Yale University
  Recruiting
• The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

  NCT03752918

  Condition:   Post Traumatic Stress Disorder
  Interventions:   Drug: MDMA;   Drug: Niacin
  Sponsor:   Yale University
  Recruiting
• Effects of E-Cigarette Flavors on Adults

  NCT03635333

  Condition:   Nicotine Use Disorder
  Interventions:   Drug: Nicotine;   Drug: Flavor
  Sponsor:   Yale University
  Recruiting
• Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

  NCT03599063

  Condition:   Healthy
  Interventions:   Biological: PF-06946860;   Other: Placebo
  Sponsor:   Pfizer
  Recruiting
• Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

  NCT03587649

  Conditions:   Alzheimer Disease;   Parkinson Disease;   Healthy Volunteers
  Intervention:   Drug: [18F]MNI-1126
  Sponsor:   Invicro
  Recruiting
• Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

  NCT03545789

  Conditions:   Healthy Volunteers;   Alzheimer Disease;   Progressive Supranuclear Palsy
  Intervention:   Drug: [18F]MNI-958
  Sponsor:   Invicro
  Recruiting
• Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

  NCT03527485

  Conditions:   Opiate Dependence;   Cocaine Dependence
  Intervention:   Diagnostic Test: 11UCB-J PET Scan
  Sponsor:   Yale University
  Recruiting
• Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

  NCT03471182

  Condition:   Cocaine Dependence
  Interventions:   Behavioral: Psychiatric and Cognitive Testing;   Drug: Cocaine Self-adminstration;   Radiation: Positron Emission Tomography;   Other: Magnetic Resonance Imaging
  Sponsor:   Yale University
  Recruiting
• Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose

  NCT03469492

  Condition:   Hyperglycaemia (Diabetic)
  Interventions:   Drug: Insulin;   Behavioral: exercise;   Dietary Supplement: Dietary counseling
  Sponsor:   Yale University
  Recruiting
• Mavoglurant in Alcohol Drinking

  NCT03327792

  Condition:   Alcohol Drinking
  Interventions:   Drug: Mavoglurant;   Drug: Placebo
  Sponsor:   Yale University
  Recruiting
• The Neural Correlates of Cannabis Use

  NCT03104257

  Conditions:   Cannabis Dependence;   Healthy
  Intervention:   Other: [11-C]OMAR
  Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA)
  Recruiting
• Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

  NCT03103750

  Condition:   ADHD
  Interventions:   Procedure: Magnetic Resonance Imaging (MRI);   Drug: Raclopride;   Dietary Supplement: calcitriol;   Drug: Placebo oral capsule;   Procedure: high-resolution research tomography;   Drug: Dextro Amphetamine
  Sponsors:   Yale University;   Brain & Behavior Research Foundation
  Recruiting
• Imaging SV2A in Mood Disorders

  NCT02734602

  Conditions:   Major Depressive Disorder;   Post-Traumatic Stress Disorder
  Interventions:   Drug: Ketamine;   Behavioral: Cognitive Testing;   Radiation: PET;   Device: MRI
  Sponsors:   Yale University;   VA Office of Research and Development
  Recruiting
• Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse

  NCT02616094

  Condition:   Alcohol Dependence
  Interventions:   Device: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1;   Device: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2
  Sponsor:   Yale University
  Recruiting
• Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

  NCT02124941

  Conditions:   Cocaine Dependence;   Healthy
  Interventions:   Drug: N-acetyl cysteine;   Diagnostic Test: [18F]FDG PET scan;   Diagnostic Test: 1H MRS;   Diagnostic Test: [11C]APP311 PET scan
  Sponsor:   Yale University
  Recruiting
• Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

  NCT02047539

  Condition:   Clinical High Risk for Psychosis
  Interventions:   Drug: Aspirin;   Drug: Placebo
  Sponsor:   Yale University
  Recruiting
• Intervention to Reduce Diaper Need and Increase Use of Pediatric Preventive Care

  NCT03490045

  Conditions:   Diaper Dermatitis;   Urinary Tract Infections;   Infection;   Depressive Symptoms;   Stress
  Interventions:   Other: Diaper Incentive;   Other: Conditional Cash Transfer Condition
  Sponsors:   Yale University;   Yale New Haven Hospital;   National Diaper Bank Network
  Recruiting
• Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

  NCT01730781

  Conditions:   Schizophrenia;   Cannabis Dependence;   Prodromal for Psychotic Illness;   Family History of Alcoholism;   Healthy Control
  Intervention:   Radiation: [11-C]OMAR
  Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
  Recruiting
• Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

  NCT04057807

  Condition:   Alzheimer Disease
  Intervention:   Drug: LPS
  Sponsor:   Yale University
  Recruiting
• Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

  NCT04057001

  Conditions:   Liver Transplant; Complications;   Hepatitis C
  Intervention:  
  Sponsor:   Yale University
  Recruiting
• Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring

  NCT04017702

  Condition:   Respiratory Depression
  Intervention:   Device: Expiron respirator
  Sponsor:   Yale University
  Recruiting
• SV2 PET Imaging With [11C]APP311

  NCT03995121

  Conditions:   Schizophrenia and Other Psychotic Disorders;   Cannabis Use Disorder;   Healthy
  Intervention:   Radiation: [11C]APP311
  Sponsor:   Yale University
  Recruiting
• Ivabradine for Rate Control in Permanent Atrial Fibrillation

  NCT03987204

  Conditions:   Atrial Fibrillation;   Atrial Fibrillation, Persistent
  Intervention:   Drug: Ivabradine
  Sponsor:   Yale University
  Recruiting
• Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

  NCT03978156

  Condition:   Sickle Cell Disease
  Interventions:   Drug: Dronabinol;   Drug: Placebo oral tablet
  Sponsor:   Yale University
  Recruiting
• The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

  NCT03965130

  Condition:   Healthy Participants
  Intervention:   Drug: Glucagon
  Sponsors:   Yale University;   Merck Sharp & Dohme Corp.
  Recruiting
• Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

  NCT03958409

  Conditions:   Skeletal Anomalies;   Kidney Transplant; Complications
  Interventions:   Diagnostic Test: measurements to evaluate metabolic bone disease;   Diagnostic Test: standard care
  Sponsor:   Yale University
  Recruiting
• A Study of the Effects of LY3372689 on the Brain in Healthy Participants

  NCT03944031

  Condition:   Healthy
  Interventions:   Drug: LY3372689;   Diagnostic Test: [18F]LSN3316612
  Sponsor:   Eli Lilly and Company
  Recruiting
• Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

  NCT03910543

  Conditions:   Cutaneous Sarcoidosis;   Granuloma Annulare
  Intervention:   Drug: Tofacitinib 5 mg twice daily
  Sponsors:   Yale University;   Pfizer
  Recruiting
• Imaging mGluR5 and Synaptic Density in Psychiatric Disorders

  NCT03898297

  Conditions:   Major Depressive Disorder;   Bipolar Disorder;   Healthy
  Interventions:   Radiation: [18F]FPEB;   Radiation: [11C]APP311
  Sponsor:   Yale University
  Recruiting
• Fatherhood Focused Family Violence Education Program

  NCT03883932

  Condition:   Domestic Violence
  Interventions:   Behavioral: Fatherhood Focused FVEP (F3);   Behavioral: Family Violence Education Program (FVEP)
  Sponsor:   Yale University
  Recruiting
• Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients

  NCT03872141

  Conditions:   Breast Cancer;   Chemotherapy Induced Peripheral Neuropathy;   Paclitaxel Induced Neuropathy
  Intervention:   Diagnostic Test: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
  Sponsor:   Yale University
  Recruiting
• Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF

  NCT03810638

  Condition:   Heart Failure
  Intervention:  
  Sponsor:   Yale University
  Recruiting
• The EXPLORE MG Registry for Myasthenia Gravis

  NCT03792659

  Condition:   Myasthenia Gravis
  Intervention:   Other: Blood Sample Draw
  Sponsor:   Yale University
  Recruiting
• Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

  NCT03764098

  Condition:   Alcohol Use
  Interventions:   Drug: Guanfacine ER;   Other: Placebo
  Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• Stress Reduction Study for Partners of Early Stage Dementia

  NCT03691428

  Condition:   Dementia Caregiving
  Intervention:   Behavioral: Wish Outcome Obstacle Plan
  Sponsors:   Yale University;   National Institute on Aging (NIA)
  Recruiting
• Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients

  NCT03684460

  Condition:   Circadian Rhythm Disorders
  Interventions:   Device: Daytime Bright Light;   Device: Usual Light
  Sponsor:   Yale University
  Recruiting
• Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

  NCT03684187

  Condition:   Primary Biliary Cholangitis
  Intervention:   Behavioral: Mindfulness Based Intervention
  Sponsor:   Yale University
  Recruiting
• Peer Wellness Enhancement For Patients With Serious Mental Illness and High Medical Costs

  NCT03673852

  Condition:   Chronic Medical Condition
  Interventions:   Behavioral: WE Harambee;   Behavioral: Behavioral Health Home Enrollment
  Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
  Recruiting
• Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?

  NCT03588754

  Condition:   Alcohol Drinking
  Interventions:   Drug: Propranolol;   Drug: Placebo
  Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

  NCT03539900

  Condition:   Binge-Eating Disorder
  Interventions:   Drug: Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination;   Other: Placebo
  Sponsors:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

  NCT03535883

  Conditions:   Pleural Effusion;   Thoracic Effusion
  Intervention:   Drug: Novel Oral Anti-Coagulants
  Sponsor:   Yale University
  Recruiting
• A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

  NCT03526185

  Condition:   Metastatic Melanoma
  Interventions:   Drug: Tumor Infiltrating Lymphocytes;   Drug: Nivolumab and Ipilimumab
  Sponsor:   Yale University
  Recruiting
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

  NCT03502330

  Conditions:   Advanced Melanoma;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma
  Interventions:   Drug: APX005M;   Drug: Cabiralizumab;   Drug: Nivolumab
  Sponsors:   Yale University;   Bristol-Myers Squibb;   Apexigen, Inc.
  Recruiting
• Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

  NCT03494010

  Condition:   Diabetes, Type 1
  Intervention:   Other: Observation
  Sponsor:   Yale University
  Recruiting
• Effect of CT1812 Treatment on Brain Synaptic Density

  NCT03493282

  Condition:   Alzheimer Disease
  Interventions:   Drug: Active Treatment- CT1812 100 mg;   Drug: Placebo;   Drug: Active Treatment- CT1812 300 mg
  Sponsor:   Cognition Therapeutics
  Recruiting
• CBT4CBT With Spanish Alcohol Users

  NCT03474588

  Condition:   Alcohol Use Disorder
  Interventions:   Behavioral: Standard treatment (ST) PLUS web-based CBT4CBT;   Behavioral: Standard Treatment (ST)
  Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure

  NCT03446651

  Condition:   Heart Failure
  Interventions:   Drug: Lysine Chloride;   Other: Placebo
  Sponsor:   Yale University
  Recruiting
• Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

  NCT03440970

  Condition:   Decompensated Heart Failure
  Interventions:   Drug: Lysine Chloride;   Other: Placebo
  Sponsor:   Yale University
  Recruiting
• Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

  NCT03367533

  Condition:   Depressive Disorder, Major
  Interventions:   Drug: Ketamine;   Drug: Perampanel;   Drug: Placebo
  Sponsor:   Yale University
  Recruiting
• An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

  NCT03359174

  Condition:   Cholangitis, Sclerosing
  Intervention:   Drug: All-trans retinoic acid
  Sponsor:   Yale University
  Recruiting
• Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

  NCT03293290

  Condition:   HIV Infections
  Intervention:   Drug: PrEP
  Sponsor:   Yale University
  Recruiting
• Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs

  NCT03282890

  Conditions:   Risk Behavior;   HIV/AIDS;   Medication Adherence;   Substance Abuse
  Intervention:   Other: CHRP-BB
  Sponsors:   University of Connecticut;   National Institute on Drug Abuse (NIDA);   APT Foundation, Inc.
  Recruiting
• Patient Driven Recovery With Nalmefene and Coaching

  NCT03279562

  Conditions:   Opioid-use Disorder;   Harmful; Use, Alcohol
  Intervention:   Drug: Nalmefene
  Sponsors:   Yale University;   First Pavlov State Medical University in St. Petersburg, Russia
  Recruiting
• Pregnancy, Mindfulness, and Massage

  NCT03276208

  Conditions:   Tobacco Use;   Pregnancy Related
  Interventions:   Other: Prenatal Massage;   Other: Mindfulness
  Sponsors:   Yale University;   Massage Therapy Foundation
  Recruiting
• Toradol to Reduce Ureteroscopic Symptoms Trial

  NCT03111381

  Conditions:   Urinary Lithiasis;   Kidney Diseases;   Kidney Stone;   Pain, Postoperative
  Intervention:   Drug: Toradol
  Sponsor:   Yale University
  Recruiting
• Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

  NCT03071224

  Conditions:   Alzheimer Disease;   Healthy Volunteers
  Interventions:   Drug: [18F] MNI-946;   Drug: [18F]Florbetapir
  Sponsor:   Invicro
  Recruiting
• Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

  NCT03045341

  Conditions:   Binge-eating Disorder;   Obesity
  Interventions:   Drug: NB medication (Naltrexone Bupropion combination);   Behavioral: Behavioral Weight Loss (BWL) counseling;   Other: Placebo
  Sponsors:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

  NCT02979977

  Condition:   Squamous Cell Cancers of the Head and Neck
  Interventions:   Drug: cetuximab;   Drug: afatinib
  Sponsors:   Yale University;   National Comprehensive Cancer Network;   Boehringer Ingelheim
  Recruiting
• Optimizing Tobacco Dependence Treatment in the Emergency Department

  NCT02896400

  Condition:   Tobacco Use Disorder
  Interventions:   Behavioral: Brief Negotiated Interview (BNI);   Drug: Nicotine replacement therapy (NRT);   Other: CT Smokers Quitline (QL);   Other: SmokefreeText (Text)
  Sponsors:   Yale University;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
  Recruiting
• Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

  NCT02864147

  Conditions:   Cervical Intraepithelial Neoplasia;   Cervical Dysplasia
  Interventions:   Drug: 9-valent HPV vaccine;   Drug: Imiquimod
  Sponsor:   Yale University
  Recruiting
• TAS-OX for Refractory Metastatic Colon Cancer

  NCT02848079

  Condition:   Colorectal Neoplasms
  Intervention:   Drug: combined TAS-102 and TAS-OX
  Sponsor:   Yale University
  Recruiting
• Optimizing Electronic Alerts for Acute Kidney Injury

  NCT02753751

  Condition:   Acute Kidney Injury
  Intervention:   Other: AKI Alert
  Sponsor:   Yale University
  Recruiting
• Examination of Glutamate and mGluR5 in Psychiatric Disorders

  NCT02727972

  Conditions:   Major Depressive Disorder;   Post-Traumatic Stress Disorder;   Bipolar Disorder
  Interventions:   Behavioral: Cognitive Testing;   Other: MRI;   Radiation: PET
  Sponsors:   Yale University;   VA Office of Research and Development
  Recruiting
• Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

  NCT02546583

  Condition:   Heart Failure
  Interventions:   Drug: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide);   Drug: IV Chlorothiazide
  Sponsor:   Yale University
  Recruiting
• Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

  NCT02489448

  Condition:   Breast Neoplasms
  Intervention:   Drug: MEDI4736
  Sponsor:   Yale University
  Recruiting
• Neurofeedback for Obsessive-Compulsive Disorder (OCD)

  NCT02206945

  Condition:   Obsessive-Compulsive Disorder
  Interventions:   Behavioral: neurofeedback;   Behavioral: control feedback
  Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
  Recruiting
• Active Surveillance of the Small Renal Mass

  NCT02204800

  Condition:   Small Renal Mass, Kidney Cancer
  Intervention:  
  Sponsor:   Yale University
  Recruiting
• The Effects of a Moderate Weight Loss on Insulin Resistance

  NCT02193295

  Condition:   Insulin Resistance
  Intervention:   Behavioral: Dietary consultations
  Sponsors:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

  NCT03842800

  Condition:   Cognitive Impairment
  Interventions:   Other: MRI;   Drug: Ketamine
  Sponsor:   Yale University
  Recruiting
• Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

  NCT03195400

  Conditions:   IGT - Impaired Glucose Tolerance;   T2D
  Interventions:   Diagnostic Test: Oral Glucose Tolerance Test;   Diagnostic Test: Hyperglycemic Clamp;   Diagnostic Test: Isoglycemic Intravenous Glucose Test;   Diagnostic Test: Hyperinsulinemic Euglycemic Clamp and 2H20
  Sponsor:   Yale University
  Recruiting
• Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)

  NCT03183388

  Condition:   Mood Disorders
  Intervention:   Behavioral: BE-SMART
  Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
  Recruiting
• Evaluation of the Implementation and Effectiveness of IPP-HPV

  NCT02994290

  Condition:   HPV Vaccination
  Interventions:   Drug: HPV vaccine;   Behavioral: Inpatient Postpartum HPV Immunization Quality Improvement Program
  Sponsor:   Yale University
  Recruiting
• Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents

  NCT02395003

  Condition:   Pediatric Obesity
  Intervention:   Other: Palmitate Diet
  Sponsor:   Yale University
  Recruiting
• Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children

  NCT01967849

  Conditions:   Obesity;   Type 2 Diabetes
  Intervention:   Diagnostic Test: Oral Glucose tolerance test
  Sponsors:   Yale University;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes

  NCT03714451

  Condition:   Diabetes Type 2
  Interventions:   Dietary Supplement: onyx sorghum;   Dietary Supplement: whole wheat flour
  Sponsor:   Yale University
  Recruiting
• A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus

  NCT03937453

  Conditions:   Pancreatic Cancer;   Pancreatic Neoplasms
  Intervention:   Diagnostic Test: MRI/MRCP
  Sponsors:   Western Connecticut Health Network;   Yale University
  Recruiting
• Nutrition and Prostate Cancer

  NCT03532308

  Condition:   Prostate Cancer
  Interventions:   Drug: Fermented Soy;   Other: Placebo
  Sponsor:   Yale University
  Recruiting
• Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

  NCT03225664

  Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Unresectable Lung Non-Small Cell Carcinoma
  Interventions:   Biological: Pembrolizumab;   Other: Pharmacokinetic Study;   Drug: Trametinib
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

  NCT02930109

  Condition:   Acute Leukemia
  Interventions:   Drug: PTX-200;   Drug: Cytarabine
  Sponsor:   Prescient Therapeutics, Ltd.
  Recruiting
• Pembrolizumab in HNSCC With Residual Disease After Radiation

  NCT02892201

  Condition:   Head and Neck Squamous Cell Carcinoma
  Intervention:   Drug: Pembrolizumab
  Sponsors:   Yale University;   Merck Sharp & Dohme Corp.
  Recruiting
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer

  NCT02681549

  Conditions:   Melanoma;   Non-small Cell Lung Cancer;   Brain Metastasis
  Intervention:   Drug: Pembrolizumab plus Bevacizumab
  Sponsor:   Yale University
  Recruiting
• A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

  NCT02665143

  Condition:   Relapsed/Refractory Acute Myeloid Leukemia
  Interventions:   Drug: nintedanib and AML induction;   Drug: AML induction (placebo)
  Sponsors:   Yale University;   Vanderbilt University
  Recruiting
• Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)

  NCT02658032

  Conditions:   Smoking Cessation;   Biofeedback
  Interventions:   Behavioral: personalized cessation care;   Behavioral: bio feedback;   Other: standard care
  Sponsor:   Yale University
  Recruiting
• Patient and Parent Preferences for an On-Body Automated Insulin Delivery System

  NCT03534544

  Condition:   Diabetes Mellitus, Type 1
  Intervention:  
  Sponsors:   Joslin Diabetes Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game

  NCT02118649

  Condition:   Neurodevelopmental Disorders
  Intervention:   Behavioral: Game
  Sponsor:   Yale University
  Recruiting
• De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation

  NCT02056054

  Condition:   De Novo Autoimmune Hepatitis
  Interventions:   Other: Pediatric transplant subject with d-AIH;   Other: Pediatric transplant subject with acute rejection;   Other: Pediatric transplant subject with chronic rejection;   Other: Adult non-transplant patients with auto-immune hepatitis;   Other: Adult non-transplant subjects with chronic hepatitis C virus;   Other: Pediatric control subjects;   Other: Adult transplanted subjects with de novo autoimmune hepatitis
  Sponsor:   Yale University
  Recruiting
• The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis

  NCT02050646

  Condition:   Autoimmune Hepatitis
  Interventions:   Other: Low Salt Diet;   Other: Liberal salt diet
  Sponsor:   Yale University
  Recruiting
• Shared Decision Making to Improve Goals-of-Care Decisions for Families of Severe Acute Brain Injury Patients

  NCT03833375

  Conditions:   Traumatic Brain Injury;   Ischemic Stroke;   Intracerebral Hemorrhage
  Intervention:   Other: Decision Aid
  Sponsors:   University of Massachusetts, Worcester;   Yale University;   University of Florida;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

  NCT03410875

  Conditions:   Hairy Cell Leukemia;   Leukemia;   Leukemia, Hairy Cell
  Interventions:   Drug: Vemurafenib;   Drug: Obinutuzumab
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Dana-Farber Cancer Institute;   Yale University
  Recruiting
• Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

  NCT03023722

  Condition:   Pancreatic Cancer
  Intervention:   Drug: anetumab ravtansine
  Sponsors:   Yale University;   Bayer
  Recruiting
• RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

  NCT03445650

  Condition:   Sjogren-Larsson Syndrome
  Interventions:   Drug: ADX-102 1% Topical Dermal Cream (reproxalap);   Drug: Vehicle of ADX-102 Topical Dermal Cream
  Sponsor:   Aldeyra Therapeutics, Inc.
  Recruiting
• Natural History of Wilson Disease

  NCT03334292

  Condition:   Wilson Disease
  Intervention:  
  Sponsor:   Yale University
  Recruiting
• Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

  NCT03770260

  Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
  Interventions:   Drug: Ixazomib Citrate;   Drug: Pevonedistat
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)

  NCT03386487

  Condition:   Cannabis Use Disorder
  Interventions:   Drug: PF 04457845;   Drug: Placebo Oral Tablet
  Sponsors:   Yale University;   Columbia University;   Johns Hopkins University;   Medical University of South Carolina
  Recruiting
• Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

  NCT02120365

  Condition:   Alcoholism
  Interventions:   Drug: Perampanel;   Drug: Placebo
  Sponsors:   Virginia Commonwealth University;   University of Connecticut;   Yale University
  Recruiting
• The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation

  NCT03982420

  Conditions:   Carotid Artery Diseases;   Carotid Atherosclerosis;   Carotid Stenosis;   Carotid Artery Plaque;   Carotid Disease
  Intervention:   Procedure: Transcarotid Revascularization (TCAR)
  Sponsors:   Silk Road Medical;   Indiana University;   University of Navarra;   Stanford University
  Recruiting
• A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer.

  NCT03888612

  Condition:   Prostate Cancer Metastatic
  Intervention:   Drug: ARV-110
  Sponsor:   Arvinas Inc
  Recruiting
• PROactive Evaluation of Function to Avoid CardioToxicity

  NCT03862131

  Conditions:   Cardiotoxicity;   Breast Cancer;   Lymphoma;   Sarcoma
  Intervention:   Device: MyoStrain®
  Sponsors:   Washington University School of Medicine;   Myocardial Solutions
  Recruiting
• CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

  NCT03798678

  Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
  Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Glutaminase Inhibitor CB-839 Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Online Therapy for Posttraumatic Stress Symptoms in WTC Responders and Survivors

  NCT03154151

  Condition:   Post-Traumatic Stress Disorder
  Interventions:   Behavioral: Online Cognitive-Behavioral Therapy;   Behavioral: Online Supportive Therapy
  Sponsors:   Icahn School of Medicine at Mount Sinai;   National Institute for Occupational Safety and Health (NIOSH/CDC)
  Recruiting
• OLAParib COmbinations

  NCT02576444

  Condition:   Cancer
  Interventions:   Drug: AZD2281;   Drug: AZD5363;   Drug: AZD1775;   Drug: AZD6738
  Sponsors:   Joseph Paul Eder;   Dana-Farber Cancer Institute;   Vanderbilt-Ingram Cancer Center;   The Cleveland Clinic
  Recruiting
• Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer

  NCT03941093

  Condition:   Pancreatic Cancer Non-resectable
  Interventions:   Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel;   Drug: Placebo + Gemcitabine + Nab-paclitaxel
  Sponsor:   FibroGen
  Recruiting
• A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

  NCT03922477

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Atezolizumab;   Drug: Hu5F9-G4
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

  NCT02907944

  Condition:   Substance-related Disorders
  Intervention:   Behavioral: Implementation Facilitation
  Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA)
  Recruiting
• Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

  NCT02900352

  Condition:   Alcohol Use Disorder
  Interventions:   Drug: Zonisamide;   Drug: Placebo
  Sponsors:   Virginia Commonwealth University;   University of Connecticut;   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   VA Connecticut Healthcare System
  Recruiting
• A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

  NCT01305499

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Entinostat days 3, 10;   Drug: 5AC;   Drug: Entinostat days 10,17
  Sponsor:   Hetty Carraway
  Recruiting
• Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

  NCT02503722

  Conditions:   EGFR Activating Mutation;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.G719X;   EGFR NP_005219.2:p.L858R;   EGFR NP_005219.2:p.L861Q;   EGFR T790M Mutation Negative;   Recurrent Lung Non-Small Cell Carcinoma;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

  NCT02453620

  Conditions:   Breast Adenocarcinoma;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Metastatic Breast Carcinoma;   Metastatic Malignant Solid Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Unresectable Solid Neoplasm
  Interventions:   Drug: Entinostat;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Pharmacogenomic Study;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693

  Condition:   B Acute Lymphoblastic Leukemia
  Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

  NCT03978689

  Conditions:   Head and Neck Cancer;   HPV Positive Oropharyngeal Squamous Cell Carcinoma;   HPV-Related Carcinoma
  Intervention:   Drug: CUE-101
  Sponsor:   Cue Biopharma
  Recruiting
• A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

  NCT03834584

  Condition:   Lymphoma
  Intervention:   Drug: AG-636
  Sponsor:   Agios Pharmaceuticals, Inc.
  Recruiting
• A Study of LY3405105 in Participants With Advanced Cancer

  NCT03770494

  Condition:   Solid Tumor
  Intervention:   Drug: LY3405105
  Sponsor:   Eli Lilly and Company
  Recruiting
• Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

  NCT03680560

  Conditions:   Solid Tumor;   HER-2 Protein Overexpression
  Interventions:   Biological: ACTR T Cell Product;   Drug: Trastuzumab
  Sponsor:   Unum Therapeutics Inc.
  Recruiting
• ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

  NCT03113968

  Conditions:   Treatment Resistant Depression;   Electroconvulsive Therapy;   ECT;   Ketamine;   Psychiatric Disorder;   Depression;   Major Depressive Disorder;   Major Depressive Episode;   Unipolar Depression
  Interventions:   Procedure: electroconvulsive therapy (ECT);   Drug: Ketamine
  Sponsors:   The Cleveland Clinic;   Patient-Centered Outcomes Research Institute
  Recruiting
• Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies

  NCT03739931

  Condition:   Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
  Interventions:   Biological: mRNA-2752;   Biological: mRNA-2752 + durvalumab;   Biological: mRNA-2752 + tremelimumab
  Sponsors:   ModernaTX, Inc.;   AstraZeneca
  Recruiting
• A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

  NCT03665285

  Conditions:   Advanced or Metastatic Solid Tumors;   Head and Neck Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer
  Intervention:   Drug: NC318
  Sponsor:   NextCure, Inc.
  Recruiting
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

  NCT03621982

  Conditions:   Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content;   Head and Neck Cancer;   Non-small Cell Lung Cancer;   Gastric Cancer;   Esophageal Cancer;   Pancreas Cancer;   Bladder Cancer;   Renal Cell Carcinoma;   Melanoma;   Triple-negative Breast Cancer;   Ovarian Cancer;   Colo-rectal Cancer
  Intervention:   Drug: ADCT-301
  Sponsor:   ADC Therapeutics S.A.
  Recruiting
• An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

  NCT03444753

  Condition:   Advanced Cancer
  Interventions:   Drug: BMS-986299;   Biological: Nivolumab;   Biological: Ipilimumab
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

  NCT03490032

  Condition:   Prostate Cancer Metastatic
  Intervention:   Drug: 68Ga-PSMA-R2
  Sponsor:   Advanced Accelerator Applications
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

  NCT00351611

  Condition:   Epilepsies, Partial
  Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
  Sponsor:   Pfizer
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure

  NCT02936752

  Conditions:   Blasts 21-30 Percent of Bone Marrow Nucleated Cells;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
  Interventions:   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

  NCT03102047

  Condition:   Rectal Cancer
  Intervention:   Drug: durvalumab
  Sponsor:   NSABP Foundation Inc
  Recruiting
• M6620, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT02567422

  Conditions:   Head and Neck Squamous Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
  Interventions:   Drug: ATR Kinase Inhibitor M6620;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

  NCT02520791

  Conditions:   Follicular T-Cell Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Stage IB Mycosis Fungoides AJCC v7;   Stage II Mycosis Fungoides AJCC v7;   Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage III Mycosis Fungoides AJCC v7;   Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides AJCC v7
  Interventions:   Biological: Anti-ICOS Monoclonal Antibody MEDI-570;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

  NCT03047213

  Conditions:   Metastatic Transitional Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   TSC1 Gene Mutation;   TSC2 Gene Mutation
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Sapanisertib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  NCT03978520

  Condition:   Systemic Lupus Erythematosus (SLE)
  Interventions:   Drug: ABBV-105;   Drug: Placebo for ABBV-105;   Drug: Upadacitinib;   Drug: Placebo for upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

  NCT03030378

  Conditions:   Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Recombinant Interleukin-12
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

  NCT02971501

  Conditions:   EGFR Activating Mutation;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Lung Carcinoma Metastatic in the Brain;   Lung Non-Small Cell Carcinoma
  Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   PD-L1 Positive;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

  NCT03768063

  Condition:   Cancer
  Intervention:   Drug: Atezolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

  NCT03712605

  Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Resected Mass
  Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Savolitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer

  NCT03592641

  Conditions:   BRAF V600 Wild Type;   c-MET Gene Amplification;   Colon Adenocarcinoma;   Colorectal Carcinoma;   KRAS wt Allele;   NRAS wt Allele;   Rectal Adenocarcinoma;   Stage III Colon Cancer AJCC v8;   Stage III Rectal Cancer AJCC v8;   Stage IIIA Colon Cancer AJCC v8;   Stage IIIA Rectal Cancer AJCC v8;   Stage IIIB Colon Cancer AJCC v8;   Stage IIIB Rectal Cancer AJCC v8;   Stage IIIC Colon Cancer AJCC v8;   Stage IIIC Rectal Cancer AJCC v8;   Stage IV Colon Cancer AJCC v8;   Stage IV Rectal Cancer AJCC v8;   Stage IVA Colon Cancer AJCC v8;   Stage IVA Rectal Cancer AJCC v8;   Stage IVB Colon Cancer AJCC v8;   Stage IVB Rectal Cancer AJCC v8;   Stage IVC Colon Cancer AJCC v8;   Stage IVC Rectal Cancer AJCC v8
  Intervention:   Drug: Savolitinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

  NCT03212274

  Conditions:   Advanced Malignant Solid Neoplasm;   Glioblastoma;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Recurrent Cholangiocarcinoma;   Recurrent Glioma;   Recurrent Malignant Solid Neoplasm;   WHO Grade II Glioma;   WHO Grade III Glioma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

  NCT02498613

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Progesterone Receptor Negative;   Stage III Breast Cancer AJCC v7;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage III Lung Small Cell Carcinoma AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Small Cell Carcinoma AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Small Cell Carcinoma AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Small Cell Carcinoma AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma;   Unresectable Pancreatic Carcinoma
  Interventions:   Other: 18F-Fluoromisonidazole;   Drug: Cediranib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
  Sponsors:   National Cancer Institute (NCI);   AstraZeneca
  Recruiting
• Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

  NCT03304639

  Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
  Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

  NCT03269669

  Conditions:   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Prednisone;   Drug: Umbralisib;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456

  Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
  Interventions:   Device: Orbital Atherectomy;   Device: Balloon
  Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
  Recruiting
• Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

  NCT03008278

  Conditions:   Metastatic Esophageal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Progressive Disease;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Gastroesophageal Junction Adenocarcinoma;   Stage III Esophageal Cancer AJCC v7;   Stage III Gastric Cancer AJCC v7;   Stage IIIA Esophageal Cancer AJCC v7;   Stage IIIA Gastric Cancer AJCC v7;   Stage IIIB Esophageal Cancer AJCC v7;   Stage IIIB Gastric Cancer AJCC v7;   Stage IIIC Esophageal Cancer AJCC v7;   Stage IIIC Gastric Cancer AJCC v7;   Stage IV Esophageal Cancer AJCC v7;   Stage IV Gastric Cancer AJCC v7;   Unresectable Esophageal Carcinoma;   Unresectable Gastric Carcinoma;   Unresectable Gastroesophageal Junction Adenocarcinoma
  Interventions:   Drug: Olaparib;   Biological: Ramucirumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer

  NCT02849496

  Conditions:   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Homologous Recombination Deficiency;   Locally Advanced Unresectable Breast Carcinoma;   Metastatic Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Atezolizumab;   Drug: Olaparib;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• The National Myelodysplastic Syndromes (MDS) Study

  NCT02775383

  Condition:   Myelodysplastic Syndromes (MDS)
  Intervention:   Other: Therapeutic
  Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
  Recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Collection and Storage of Tissue and Blood Samples From Patients With Cancer

  NCT02474160

  Conditions:   Lymphoma;   Malignant Neoplasm;   Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Plasma Cell Leukemia;   Plasma Cell Myeloma;   Progressive Disease;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Spread of Lymphoma
  Intervention:   Other: Cytology Specimen Collection Procedure
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

  NCT02595931

  Conditions:   Advanced Malignant Solid Neoplasm;   Metastatic Malignant Neoplasm;   Refractory Malignant Neoplasm;   Unresectable Malignant Neoplasm
  Interventions:   Drug: ATR Kinase Inhibitor M6620;   Drug: Irinotecan;   Drug: Irinotecan Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

  NCT02314169

  Conditions:   Anal Canal Squamous Cell Carcinoma;   Metastatic Anal Canal Carcinoma;   Stage IV Anal Canal Cancer AJCC v6 and v7
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy

  NCT02275533

  Condition:   Acute Myeloid Leukemia in Remission
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   BRAF NP_004324.2:p.V600X;   Metastatic Melanoma;   Progressive Disease;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

  NCT01805076

  Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
  Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
  Recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

  NCT03258931

  Condition:   Newly Diagnosed FLT3 Mutated AML
  Interventions:   Drug: Crenolanib;   Drug: Midostaurin;   Drug: Cytarabine;   Drug: Duanorubicin
  Sponsor:   Arog Pharmaceuticals, Inc.
  Recruiting
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

  NCT03523728

  Condition:   Polycystic Kidney, Autosomal Dominant
  Interventions:   Drug: Venglustat GZ402671;   Drug: Placebo
  Sponsor:   Genzyme, a Sanofi Company
  Recruiting
• MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

  NCT03531632

  Condition:   Colorectal Cancer Metastatic
  Intervention:   Biological: MGD007 + MGA012
  Sponsor:   MacroGenics
  Recruiting
• A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors

  NCT03522142

  Condition:   Advanced Solid Tumors
  Interventions:   Drug: INCB081776;   Drug: Nivolumab
  Sponsor:   Incyte Corporation
  Recruiting
• This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)

  NCT03449381

  Condition:   Neoplasms
  Intervention:   Drug: BI 907828
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss

  NCT03435250

  Conditions:   Advanced Solid Tumors;   Lymphoma
  Intervention:   Drug: AG-270
  Sponsor:   Agios Pharmaceuticals, Inc.
  Recruiting
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

  NCT02688985

  Conditions:   Relapsing Multiple Sclerorsis;   Multiple Sclerosis, Primary Progressive
  Interventions:   Drug: Ocrelizumab;   Procedure: Lumbar Puncture;   Drug: Methyloprednisolone;   Drug: Antihistamine
  Sponsor:   Genentech, Inc.
  Recruiting
• M8891 First in Human in Solid Tumors

  NCT03138538

  Condition:   Advanced Solid Tumors
  Intervention:   Drug: M8891
  Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
  Recruiting
• A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

  NCT02667873

  Condition:   Solid Tumors
  Intervention:   Drug: SL-801
  Sponsor:   Stemline Therapeutics, Inc.
  Recruiting
• A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

  NCT03669640

  Condition:   Schizophrenia, Schizoaffective Disorder
  Interventions:   Drug: RO6889450;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

  NCT03203642

  Conditions:   Autosomal Dominant Polycystic Kidney;   ADPKD
  Interventions:   Drug: Tesevatinib;   Drug: Placebo
  Sponsor:   Kadmon Corporation, LLC
  Recruiting
• A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

  NCT03382639

  Condition:   Schizophrenia
  Interventions:   Drug: TAK-831;   Drug: Placebo
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450

  Conditions:   Cancer Survivor;   Osteosarcoma
  Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

  NCT02308085

  Condition:   Early Breast Cancer
  Intervention:   Other: Endocrine therapy interruption
  Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
  Recruiting
• A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

  NCT03948763

  Conditions:   Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Pancreatic Neoplasms;   Colorectal Neoplasms
  Interventions:   Biological: V941;   Biological: Pembrolizumab
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• PF-06651600 for the Treatment of Alopecia Areata

  NCT03732807

  Condition:   Alopecia Areata
  Interventions:   Drug: PF-06651600 Induction Dose;   Drug: PF-06651600 Maintenance Dose #1;   Drug: PF-06651600 Maintenance Dose #2;   Drug: PF-06651600 Maintenance Dose #3;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Derazantinib and Atezolizumab in Patients With Urothelial Cancer

  NCT04045613

  Condition:   Urothelial Carcinoma
  Interventions:   Drug: Derazantinib;   Drug: Atezolizumab (drug supplied by Hoffmann-La Roche)
  Sponsor:   Basilea Pharmaceutica
  Recruiting
• Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

  NCT03924869

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Radiation: Stereotactic Body Radiotherapy (SBRT);   Biological: Pembrolizumab;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

  NCT03829501

  Conditions:   Squamous Cell Carcinoma of Head and Neck;   Non-small Cell Lung Cancer;   Hepatocellular Carcinoma;   Esophageal Cancer;   Gastric Cancer;   Melanoma;   Renal Cell Carcinoma;   Pancreatic Cancer;   Cervical Cancer;   Triple Negative Breast Cancer;   Advanced Cancer
  Interventions:   Drug: KY1044;   Drug: KY1044 and atezolizumab
  Sponsor:   Kymab Limited
  Recruiting
• Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT03821935

  Condition:   Advanced Solid Tumors Cancer
  Interventions:   Drug: ABBV-151;   Drug: ABBV-181
  Sponsor:   AbbVie
  Recruiting
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

  NCT03783442

  Condition:   Esophageal Squamous Cell Carcinoma (ESCC)
  Interventions:   Drug: Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU);   Drug: Platinum (cisplatin or oxaliplatin) + capecitabine;   Drug: Platinum (cisplatin or oxaliplatin) + paclitaxel
  Sponsor:   BeiGene
  Recruiting
• Study of PTC299 in Relapsed/Refractory Acute Leukemias

  NCT03761069

  Conditions:   Leukemia, Myeloid, Acute;   AML
  Intervention:   Drug: PTC299
  Sponsor:   PTC Therapeutics
  Recruiting
• A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

  NCT03726879

  Condition:   Breast Cancer
  Interventions:   Drug: Atezolizumab;   Drug: Placebo;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Trastuzumab Emtansine
  Sponsors:   Hoffmann-La Roche;   Chugai Pharmaceutical
  Recruiting
• Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

  NCT03672695

  Condition:   Acute Myeloid Leukaemia
  Intervention:   Combination Product: S 64315 (also referred as MIK665) and venetoclax
  Sponsors:   Servier;   ADIR, a Servier Group company
  Recruiting
• A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

  NCT03574571

  Condition:   Prostate Cancer
  Interventions:   Drug: Docetaxel 75 mg/m2;   Drug: Docetaxel 60 mg/m2;   Drug: Radium-223
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Bayer
  Recruiting
• A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

  NCT03565445

  Condition:   Advanced Solid Tumors
  Interventions:   Drug: ASP1948;   Drug: nivolumab
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

  NCT03539952

  Condition:   Wilson Disease
  Interventions:   Drug: TETA 4HCL;   Drug: Penicillamine
  Sponsor:   GMP-Orphan SAS
  Recruiting
• Study of ASTX029 in Subjects With Advanced Solid Tumors

  NCT03520075

  Condition:   Solid Tumor, Adult
  Intervention:   Drug: ASTX029
  Sponsor:   Astex Pharmaceuticals
  Recruiting